The Australian Immunisation Handbook 10th Edition 2013

dosage and administration, 418–419
epidemiology, 416–417
and HIV-infected persons, 159
precautions, 421–422
pregnancy and breastfeeding, 137, 139, 421
public health management, 422
recommendations, 419–420
route of vaccine administration, 68–69
transport, storage and handling, 418
and travellers, 122
vaccines, 417–418
variations from product information, 422
V
vaccination, commonly asked questions,
473–488
vaccination contraindications. see
contraindications to vaccination
vaccination documentation. see documentation
of vaccination
vaccination procedures. see procedures for
vaccination
vaccination recommendations. see under
individual disease names
vaccination status and history, 39–40
vaccine administration. see administration of
vaccines
vaccine availability in Australia, 498–499
vaccine components, commonly asked
questions about, 484–486
vaccine effectiveness, 20–21
vaccine efficacy, 20–21
vaccine failure, 20–21
Vaccine Information and Vaccine
Administration System (VIVAS), 102–103
vaccine preparation. see preparation of vaccines
vaccine product information, 5, 6, 19. see also
under individual disease names, variations from
product information
vaccine safety, 21–23. see also adverse events
following immunisation (AEFI)
commonly asked questions about, 481–483
vaccine side effects. see adverse events
following immunisation (AEFI)
vaccine-preventable diseases, 175–455. see also
under individual disease names
changes in the 10th edition of the
handbook, 11–16
cholera, 11, 176–181
diphtheria, 11–12, 182–190
Haemophilus influenzae type b (Hib), 12,
191–197
hepatitis A, 12, 198–207
hepatitis B, 12, 208–230
human papillomavirus (HPV), 13, 231–242
influenza, 13, 243–258
Japanese encephalitis, 13, 259–266
522 The Australian Immunisation Handbook 10th edition
measles, 13–14, 267–282
meningococcal disease, 14, 283–294
mumps, 13–14, 295–301
pertussis, 11–12, 302–316
pneumococcal disease, 14–15, 317–337
poliomyelitis, 15, 338–344
Q fever, 15, 345–352
rabies and other lyssaviruses (including
Australian bat lyssavirus), 15–16, 353–371
rotavirus, 16, 372–383
rubella, 13–14, 384–396
tetanus, 11–12, 397–407
tuberculosis, 16, 408–415
typhoid, 416–422
varicella, 13–14, 423–438
yellow fever, 16, 439–445
zoster (herpes zoster), 16, 446–455
vaginal cancer, 233
valid consent. see consent
valid dose. see dosage
Vaqta Adult formulation, 200
dosage and administration, 125, 202
vaccine components, 469–472
Vaqta Paediatric/Adolescent formulation, 200
dosage and administration, 202
lower age limits for, 127
vaccine components, 469–472
varicella, 423–438
adverse events following immunisation
(AEFI), 433–435
catch-up vaccination, 52, 63–64
changes in the 10th edition of the
handbook, 13–14
and children, 427–428
clinical features, 423
co-administration with other vaccines, 427
contraindications to vaccination, 431–432
dosage and administration, 49, 50, 427
epidemiology, 424
higher risk groups, 430
and HIV-infected persons, 159
interchangeability of vaccines, 427
minimum acceptable age for the 1st vaccine
dose, 47
post-exposure vaccination, 429–430, 437
precautions, 432–433
pregnancy and breastfeeding, 140, 430–431,
432
public health management, 435–437
recommendations, 427–430
serological testing for immunity, 429
transport, storage and handling, 426–427
and travellers, 118
vaccines, 68–69, 424–426
variations from product information,
437–438
virology, 423